NewAmsterdam Pharma Company N.V. announced the appointment of William ?BJ? Jones as the Company?s first Chief Commercial Officer, effective August 14, 2023. Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for brands.

At NewAmsterdam, he will build and lead all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations. Mr. Jones joins NewAmsterdam with three decades of commercial and launch experience in both large pharmaceutical and small biotech companies. Most recently, he served as CCO, Migraine & Common Diseases at Biohaven Pharmaceuticals, which was acquired by Pfizer for $11.6 Billion.

During his tenure, Mr. Jones led the commercial enterprise that launched Biohaven?s Nurtec® ODT. Earlier in his career, Mr. Jones held leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim and NitroMed, during which time he supported mass market product launches for notable brands including Excedrin Migraine, Farxig, Pradaxa, BiDil, and Abilify. Mr. Jones is a graduate of the United Air Force Academy and attained the rank of Major through his active duty and reserve service.

He holds an M.B. A from Stanford Graduate School of Business and an M.S. in Industrial Engineering from Texas A&M University.